tislelizumab,sorafenib
beigene,bayer,novartis
['tislelizumab', 'sorafenib']
#tislelizumab demonstrated non-inferior overall survival versus sorafenib in #livercancer patients. #esmo22 #esmo2022 #onctwitter #medtwitter #cancer #oncology #cancerresearch #cancertreatment #cancercare #cancerawareness #news #media #conferences #patient
iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma